1syv › Citations

Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion.

Zernich D, Purcell AW, Macdonald WA, Kjer-Nielsen L, Ely LK, Laham N, Crockford T, Mifsud NA, Bharadwaj M, Chang L, Tait BD, Holdsworth R, Brooks AG, Bottomley SP, Beddoe T, Peh CA, Rossjohn J, McCluskey J
J Exp Med 200 13-24 (2004)
Cited: 119 times
EuropePMC logo PMID: 15226359

Abstract

HLA class I polymorphism creates diversity in epitope specificity and T cell repertoire. We show that HLA polymorphism also controls the choice of Ag presentation pathway. A single amino acid polymorphism that distinguishes HLA-B*4402 (Asp116) from B*4405 (Tyr116) permits B*4405 to constitutively acquire peptides without any detectable incorporation into the transporter associated with Ag presentation (TAP)-associated peptide loading complex even under conditions of extreme peptide starvation. This mode of peptide capture is less susceptible to viral interference than the conventional loading pathway used by HLA-B*4402 that involves assembly of class I molecules within the peptide loading complex. Thus, B*4402 and B*4405 are at opposite extremes of a natural spectrum in HLA class I dependence on the PLC for Ag presentation. These findings unveil a new layer of MHC polymorphism that affects the generic pathway of Ag loading, revealing an unsuspected evolutionary trade-off in selection for optimal HLA class I loading versus effective pathogen evasion.

Articles - 1syv mentioned but not cited (11)

  1. Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. Zernich D, Purcell AW, Macdonald WA, Kjer-Nielsen L, Ely LK, Laham N, Crockford T, Mifsud NA, Bharadwaj M, Chang L, Tait BD, Holdsworth R, Brooks AG, Bottomley SP, Beddoe T, Peh CA, Rossjohn J, McCluskey J. J. Exp. Med. 200 13-24 (2004)
  2. Comparative molecular dynamics analysis of tapasin-dependent and -independent MHC class I alleles. Sieker F, Springer S, Zacharias M. Protein Sci. 16 299-308 (2007)
  3. Distinct assembly profiles of HLA-B molecules. Rizvi SM, Salam N, Geng J, Qi Y, Bream JH, Duggal P, Hussain SK, Martinson J, Wolinsky SM, Carrington M, Raghavan M. J. Immunol. 192 4967-4976 (2014)
  4. The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family. Bade-Döding C, Theodossis A, Gras S, Kjer-Nielsen L, Eiz-Vesper B, Seltsam A, Huyton T, Rossjohn J, McCluskey J, Blasczyk R. Haematologica 96 110-118 (2011)
  5. Selector function of MHC I molecules is determined by protein plasticity. Bailey A, Dalchau N, Carter R, Emmott S, Phillips A, Werner JM, Elliott T. Sci Rep 5 14928 (2015)
  6. Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. Luo H, Du T, Zhou P, Yang L, Mei H, Ng H, Zhang W, Shu M, Tong W, Shi L, Mendrick DL, Hong H. Comb Chem High Throughput Screen 18 296-304 (2015)
  7. Position 156 influences the peptide repertoire and tapasin dependency of human leukocyte antigen B*44 allotypes. Badrinath S, Saunders P, Huyton T, Aufderbeck S, Hiller O, Blasczyk R, Bade-Doeding C. Haematologica 97 98-106 (2012)
  8. Although divergent in residues of the peptide binding site, conserved chimpanzee Patr-AL and polymorphic human HLA-A*02 have overlapping peptide-binding repertoires. Gleimer M, Wahl AR, Hickman HD, Abi-Rached L, Norman PJ, Guethlein LA, Hammond JA, Draghi M, Adams EJ, Juo S, Jalili R, Gharizadeh B, Ronaghi M, Garcia KC, Hildebrand WH, Parham P. J. Immunol. 186 1575-1588 (2011)
  9. Improved pan-specific MHC class I peptide-binding predictions using a novel representation of the MHC-binding cleft environment. Carrasco Pro S, Zimic M, Nielsen M. Tissue Antigens 83 94-100 (2014)
  10. Structural Comparison Between MHC Classes I and II; in Evolution, a Class-II-Like Molecule Probably Came First. Wu Y, Zhang N, Hashimoto K, Xia C, Dijkstra JM. Front Immunol 12 621153 (2021)
  11. The Structure of a Peptide-Loaded Shark MHC Class I Molecule Reveals Features of the Binding between β2-Microglobulin and H Chain Conserved in Evolution. Wu Y, Zhang N, Wei X, Lu S, Li S, Hashimoto K, Dijkstra JM, Xia C. J Immunol 207 308-321 (2021)


Reviews citing this publication (38)

  1. More than one reason to rethink the use of peptides in vaccine design. Purcell AW, McCluskey J, Rossjohn J. Nat Rev Drug Discov 6 404-414 (2007)
  2. Regulation of MHC class I assembly and peptide binding. Peaper DR, Cresswell P. Annu. Rev. Cell Dev. Biol. 24 343-368 (2008)
  3. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. Annu. Rev. Pharmacol. Toxicol. 52 401-431 (2012)
  4. HLA and pharmacogenetics of drug hypersensitivity. Pavlos R, Mallal S, Phillips E. Pharmacogenomics 13 1285-1306 (2012)
  5. MHC class I assembly: out and about. Raghavan M, Del Cid N, Rizvi SM, Peters LR. Trends Immunol. 29 436-443 (2008)
  6. A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned. Gras S, Burrows SR, Turner SJ, Sewell AK, McCluskey J, Rossjohn J. Immunol. Rev. 250 61-81 (2012)
  7. Tapasin and other chaperones: models of the MHC class I loading complex. Wright CA, Kozik P, Zacharias M, Springer S. Biol. Chem. 385 763-778 (2004)
  8. Peptides: the cornerstone of HLA-B27 biology and pathogenetic role in spondyloarthritis. Marcilla M, López de Castro JA. Tissue Antigens 71 495-506 (2008)
  9. TAP genes and immunity. McCluskey J, Rossjohn J, Purcell AW. Curr. Opin. Immunol. 16 651-659 (2004)
  10. ERAP1 structure, function and pathogenetic role in ankylosing spondylitis and other MHC-associated diseases. Alvarez-Navarro C, López de Castro JA. Mol. Immunol. 57 12-21 (2014)
  11. The cell biology of major histocompatibility complex class I assembly: towards a molecular understanding. Van Hateren A, James E, Bailey A, Phillips A, Dalchau N, Elliott T. Tissue Antigens 76 259-275 (2010)
  12. The structural bases of direct T-cell allorecognition: implications for T-cell-mediated transplant rejection. Gras S, Kjer-Nielsen L, Chen Z, Rossjohn J, McCluskey J. Immunol. Cell Biol. 89 388-395 (2011)
  13. Structural studies on HLA-G: implications for ligand and receptor binding. Clements CS, Kjer-Nielsen L, McCluskey J, Rossjohn J. Hum. Immunol. 68 220-226 (2007)
  14. Viral immune evasion molecules attack the ER peptide-loading complex and exploit ER-associated degradation pathways. Lybarger L, Wang X, Harris M, Hansen TH. Curr. Opin. Immunol. 17 71-78 (2005)
  15. HLA associations with nasopharyngeal carcinoma. Li X, Fasano R, Wang E, Yao KT, Marincola FM. Curr. Mol. Med. 9 751-765 (2009)
  16. Molecular machinations of the MHC-I peptide loading complex. Purcell AW, Elliott T. Curr. Opin. Immunol. 20 75-81 (2008)
  17. Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes. Vigneron N, Van den Eynde BJ. Cell. Mol. Life Sci. 68 1503-1520 (2011)
  18. Recognition of open conformers of classical MHC by chaperones and monoclonal antibodies. Hansen TH, Lybarger L, Yu L, Mitaksov V, Fremont DH. Immunol. Rev. 207 100-111 (2005)
  19. Accessory molecules in the assembly of major histocompatibility complex class I/peptide complexes: how essential are they for CD8(+) T-cell immune responses? Garbi N, Tanaka S, van den Broek M, Momburg F, Hämmerling GJ. Immunol. Rev. 207 77-88 (2005)
  20. HLA variation and disease. Dendrou CA, Petersen J, Rossjohn J, Fugger L. Nat. Rev. Immunol. 18 325-339 (2018)
  21. Pathogen evasion strategies for the major histocompatibility complex class I assembly pathway. Antoniou AN, Powis SJ. Immunology 124 1-12 (2008)
  22. Viral immune evasion: Lessons in MHC class I antigen presentation. van de Weijer ML, Luteijn RD, Wiertz EJ. Semin. Immunol. 27 125-137 (2015)
  23. T cell allorecognition and MHC restriction--A case of Jekyll and Hyde? Archbold JK, Ely LK, Kjer-Nielsen L, Burrows SR, Rossjohn J, McCluskey J, Macdonald WA. Mol. Immunol. 45 583-598 (2008)
  24. Understanding the complexity and malleability of T-cell recognition. Miles JJ, McCluskey J, Rossjohn J, Gras S. Immunol. Cell Biol. 93 433-441 (2015)
  25. Proofreading of Peptide-MHC Complexes through Dynamic Multivalent Interactions. Thomas C, Tampé R. Front Immunol 8 65 (2017)
  26. The versatility of the αβ T-cell antigen receptor. Bhati M, Cole DK, McCluskey J, Sewell AK, Rossjohn J. Protein Sci. 23 260-272 (2014)
  27. Transport and quality control of MHC class I molecules in the early secretory pathway. Springer S. Curr. Opin. Immunol. 34 83-90 (2015)
  28. Plasticity of empty major histocompatibility complex class I molecules determines peptide-selector function. van Hateren A, Bailey A, Werner JM, Elliott T. Mol. Immunol. 68 98-101 (2015)
  29. TAPBPR: a new player in the MHC class I presentation pathway. Hermann C, Trowsdale J, Boyle LH. Tissue Antigens 85 155-166 (2015)
  30. HLA-B polymorphisms and intracellular assembly modes. Raghavan M, Geng J. Mol. Immunol. 68 89-93 (2015)
  31. Polymorphisms of HLA-B: influences on assembly and immunity. Olson E, Geng J, Raghavan M. Curr Opin Immunol 64 137-145 (2020)
  32. Tumour and placenta establishment: The importance of antigen processing and presentation. Reeves E, James E. Placenta 56 34-39 (2017)
  33. Dynamics of MHC-I molecules in the antigen processing and presentation pathway. Truong HV, Sgourakis NG. Curr Opin Immunol 70 122-128 (2021)
  34. The mode of action of tapasin on major histocompatibility class I (MHC-I) molecules. Lan BH, Becker M, Freund C. J Biol Chem 299 102987 (2023)
  35. Conformational sensing of major histocompatibility complex (MHC) class I molecules by immune receptors and intracellular assembly factors. Geng J, Raghavan M. Curr Opin Immunol 70 67-74 (2021)
  36. Strategies for the measurements of expression levels and half-lives of HLA class I allotypes. Raghavan M, Yarzabek B, Zaitouna AJ, Krishnakumar S, Ramon DS. Hum Immunol 80 221-227 (2019)
  37. Structural aspects of chaperone-mediated peptide loading in the MHC-I antigen presentation pathway. Natarajan K, Jiang J, Margulies DH. Crit. Rev. Biochem. Mol. Biol. 54 164-173 (2019)
  38. Variations in MHC class I antigen presentation and immunopeptidome selection pathways. Zaitoua AJ, Kaur A, Raghavan M. F1000Res 9 (2020)

Articles citing this publication (70)

  1. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, Kjer-Nielsen L, Mifsud NA, Tait BD, Holdsworth R, Almeida CA, Nolan D, Macdonald WA, Archbold JK, Kellerher AD, Marriott D, Mallal S, Bharadwaj M, Rossjohn J, McCluskey J. Immunity 28 822-832 (2008)
  2. T cell allorecognition via molecular mimicry. Macdonald WA, Chen Z, Gras S, Archbold JK, Tynan FE, Clements CS, Bharadwaj M, Kjer-Nielsen L, Saunders PM, Wilce MC, Crawford F, Stadinsky B, Jackson D, Brooks AG, Purcell AW, Kappler JW, Burrows SR, Rossjohn J, McCluskey J. Immunity 31 897-908 (2009)
  3. Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection. Chen M, Bouvier M. EMBO J. 26 1681-1690 (2007)
  4. Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, Day C, Crawford H, Honeyborne I, Asher TE, Luzzi G, Edwards A, Rousseau CM, Mullins JI, Tudor-Williams G, Novelli V, Brander C, Douek DC, Kiepiela P, Walker BD, Goulder PJ. J Immunol 177 4699-4708 (2006)
  5. Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. Archbold JK, Macdonald WA, Gras S, Ely LK, Miles JJ, Bell MJ, Brennan RM, Beddoe T, Wilce MC, Clements CS, Purcell AW, McCluskey J, Burrows SR, Rossjohn J. J. Exp. Med. 206 209-219 (2009)
  6. Redox regulation of peptide receptivity of major histocompatibility complex class I molecules by ERp57 and tapasin. Kienast A, Preuss M, Winkler M, Dick TP. Nat. Immunol. 8 864-872 (2007)
  7. Allelic polymorphism in the T cell receptor and its impact on immune responses. Gras S, Chen Z, Miles JJ, Liu YC, Bell MJ, Sullivan LC, Kjer-Nielsen L, Brennan RM, Burrows JM, Neller MA, Khanna R, Purcell AW, Brooks AG, McCluskey J, Rossjohn J, Burrows SR. J. Exp. Med. 207 1555-1567 (2010)
  8. Functional interaction of the ankylosing spondylitis-associated endoplasmic reticulum aminopeptidase 1 polymorphism and HLA-B27 in vivo. García-Medel N, Sanz-Bravo A, Van Nguyen D, Galocha B, Gómez-Molina P, Martín-Esteban A, Alvarez-Navarro C, de Castro JA. Mol. Cell Proteomics 11 1416-1429 (2012)
  9. Critical role for the tapasin-docking site of TAP2 in the functional integrity of the MHC class I-peptide-loading complex. Leonhardt RM, Keusekotten K, Bekpen C, Knittler MR. J Immunol 175 5104-5114 (2005)
  10. Peptide-receptive major histocompatibility complex class I molecules cycle between endoplasmic reticulum and cis-Golgi in wild-type lymphocytes. Garstka M, Borchert B, Al-Balushi M, Praveen PV, Kühl N, Majoul I, Duden R, Springer S. J Biol Chem 282 30680-30690 (2007)
  11. Differential tapasin dependence of MHC class I molecules correlates with conformational changes upon peptide dissociation: a molecular dynamics simulation study. Sieker F, Straatsma TP, Springer S, Zacharias M. Mol. Immunol. 45 3714-3722 (2008)
  12. Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, Jia X, Erlich RL, Lennon NJ, Kadie CM, Heckerman D, Gupta N, Haas DW, Deeks SG, Pereyra F, Walker BD, de Bakker PI, International HIV Controllers Study. Hum. Mol. Genet. 21 4334-4347 (2012)
  13. Folding of HLA-B27 subtypes is determined by the global effect of polymorphic residues and shows incomplete correspondence to ankylosing spondylitis. Galocha B, de Castro JA. Arthritis Rheum. 58 401-412 (2008)
  14. CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population. Lampen MH, Verweij MC, Querido B, van der Burg SH, Wiertz EJ, van Hall T. J Immunol 185 6508-6517 (2010)
  15. Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype. Hillen N, Mester G, Lemmel C, Weinzierl AO, Müller M, Wernet D, Hennenlotter J, Stenzl A, Rammensee HG, Stevanović S. Eur. J. Immunol. 38 2993-3003 (2008)
  16. A shared epitope of the interphotoreceptor retinoid-binding protein recognized by the CD4+ and CD8+ autoreactive T cells. Shao H, Peng Y, Liao T, Wang M, Song M, Kaplan HJ, Sun D. J. Immunol. 175 1851-1857 (2005)
  17. HIV control through a single nucleotide on the HLA-B locus. Kløverpris HN, Harndahl M, Leslie AJ, Carlson JM, Ismail N, van der Stok M, Huang KH, Chen F, Riddell L, Steyn D, Goedhals D, van Vuuren C, Frater J, Walker BD, Carrington M, Ndung'u T, Buus S, Goulder P. J. Virol. 86 11493-11500 (2012)
  18. The first step of peptide selection in antigen presentation by MHC class I molecules. Garstka MA, Fish A, Celie PH, Joosten RP, Janssen GM, Berlin I, Hoppes R, Stadnik M, Janssen L, Ovaa H, van Veelen PA, Perrakis A, Neefjes J. Proc. Natl. Acad. Sci. U.S.A. 112 1505-1510 (2015)
  19. F pocket flexibility influences the tapasin dependence of two differentially disease-associated MHC Class I proteins. Abualrous ET, Fritzsche S, Hein Z, Al-Balushi MS, Reinink P, Boyle LH, Wellbrock U, Antoniou AN, Springer S. Eur. J. Immunol. 45 1248-1257 (2015)
  20. Spondylarthritis-associated and non-spondylarthritis-associated B27 subtypes differ in their dependence upon tapasin for surface expression and their incorporation into the peptide loading complex. Goodall JC, Ellis L, Hill Gaston JS. Arthritis Rheum. 54 138-147 (2006)
  21. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. Liu J, Zhang S, Tan S, Yi Y, Wu B, Cao B, Zhu F, Wang C, Wang H, Qi J, Gao GF. J. Virol. 86 13281-13294 (2012)
  22. Functional significance of tapasin membrane association and disulfide linkage to ERp57 in MHC class I presentation. Vigneron N, Peaper DR, Leonhardt RM, Cresswell P. Eur. J. Immunol. 39 2371-2376 (2009)
  23. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer. Oerke S, Höhn H, Zehbe I, Pilch H, Schicketanz KH, Hitzler WE, Neukirch C, Freitag K, Maeurer MJ. Int. J. Cancer 114 766-778 (2005)
  24. Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms. Stewart-Jones GB, Simpson P, van der Merwe PA, Easterbrook P, McMichael AJ, Rowland-Jones SL, Jones EY, Gillespie GM. Proc. Natl. Acad. Sci. U.S.A. 109 E3483-92 (2012)
  25. Cowpox virus protein CPXV012 eludes CTLs by blocking ATP binding to TAP. Luteijn RD, Hoelen H, Kruse E, van Leeuwen WF, Grootens J, Horst D, Koorengevel M, Drijfhout JW, Kremmer E, Früh K, Neefjes JJ, Killian A, Lebbink RJ, Ressing ME, Wiertz EJ. J Immunol 193 1578-1589 (2014)
  26. The Carboxy Terminus of the Ligand Peptide Determines the Stability of the MHC Class I Molecule H-2Kb: A Combined Molecular Dynamics and Experimental Study. Abualrous ET, Saini SK, Ramnarayan VR, Ilca FT, Zacharias M, Springer S. PLoS ONE 10 e0135421 (2015)
  27. A molecular basis for the interplay between T cells, viral mutants, and human leukocyte antigen micropolymorphism. Liu YC, Chen Z, Neller MA, Miles JJ, Purcell AW, McCluskey J, Burrows SR, Rossjohn J, Gras S. J. Biol. Chem. 289 16688-16698 (2014)
  28. The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. Saunders PM, MacLachlan BJ, Pymm P, Illing PT, Deng Y, Wong SC, Oates CVL, Purcell AW, Rossjohn J, Vivian JP, Brooks AG. Proc Natl Acad Sci U S A 117 11636-11647 (2020)
  29. Assembly and intracellular trafficking of HLA-B*3501 and HLA-B*3503. Thammavongsa V, Schaefer M, Filzen T, Collins KL, Carrington M, Bangia N, Raghavan M. Immunogenetics 61 703-716 (2009)
  30. Complete coding sequences and haplotypic associations of HLA-B*0707, -B*1524, -B*4405, -B*4802, -DRB1*0409, -DRB1*0411, -DRB1*1115, -DRB1*1305, and the novel allele -DRB1*0709. Group-specific amplification of cDNA from DRB1 alleles associated to DRB3 and DRB4. Vilches C, Sepúlveda S, Balas A, Solís R, Avilés MJ, Estefanía E, Gómez-Lozano N, Vicario JL, dePablo R. Tissue Antigens 65 529-538 (2005)
  31. Coupling between side chain interactions and binding pocket flexibility in HLA-B*44:02 molecules investigated by molecular dynamics simulations. Ostermeir K, Springer S, Zacharias M. Mol. Immunol. 63 312-319 (2015)
  32. Endoplasmic reticulum chaperones stabilize ligand-receptive MR1 molecules for efficient presentation of metabolite antigens. McWilliam HEG, Mak JYW, Awad W, Zorkau M, Cruz-Gomez S, Lim HJ, Yan Y, Wormald S, Dagley LF, Eckle SBG, Corbett AJ, Liu H, Li S, Reddiex SJJ, Mintern JD, Liu L, McCluskey J, Rossjohn J, Fairlie DP, Villadangos JA. Proc Natl Acad Sci U S A 117 24974-24985 (2020)
  33. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia). Vacek MM, Schäffer AA, Davis J, Fischer RE, Dale JK, Adams S, Straus SE, Puck JM. Clin. Immunol. 118 59-65 (2006)
  34. Polymorphism, natural selection, and structural modeling of class Ia MHC in the African clawed frog (Xenopus laevis). Bos DH, Waldman B. Immunogenetics 58 433-442 (2006)
  35. Mutational analysis reveals a complex interplay of peptide binding and multiple biological features of HLA-B27. Galocha B, López de Castro JA. J. Biol. Chem. 285 39180-39190 (2010)
  36. Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches. Kunze-Schumacher H, Blasczyk R, Bade-Doeding C. J Immunol Res 2014 246171 (2014)
  37. Specificity of amyloid precursor-like protein 2 interactions with MHC class I molecules. Tuli A, Sharma M, Naslavsky N, Caplan S, Solheim JC. Immunogenetics 60 303-313 (2008)
  38. Tapasin facilitation of natural HLA-A and -B allomorphs is strongly influenced by peptide length, depends on stability, and separates closely related allomorphs. Geironson L, Thuring C, Harndahl M, Rasmussen M, Buus S, Røder G, Paulsson KM. J Immunol 191 3939-3947 (2013)
  39. A comprehensive analysis of peptides presented by HLA-A1. Giam K, Ayala-Perez R, Illing PT, Schittenhelm RB, Croft NP, Purcell AW, Dudek NL. Tissue Antigens 85 492-496 (2015)
  40. Evolution of MHC class I in the order Crocodylia. Jaratlerdsiri W, Isberg SR, Higgins DP, Ho SY, Salomonsen J, Skjodt K, Miles LG, Gongora J. Immunogenetics 66 53-65 (2014)
  41. Sequence 168 to 177 of interphotoreceptor retinoid-binding protein (IRBP) is an antigenic epitope for autoreactive CD8 T cells in the B10RIII mouse. Song L, Le J, Ye F, Shao H, Kaplan HJ, Sun D. J. Neuroimmunol. 193 68-76 (2008)
  42. Biochemical and structural impact of natural polymorphism in the HLA-A3 superfamily. Li L, Bouvier M. Mol. Immunol. 42 1331-1344 (2005)
  43. HLA-specific intracellular epitope processing shapes an immunodominance pattern for HLA-B*57 that is distinct from HLA-B*58:01. Kløverpris HN, Stryhn A, Harndahl M, Payne R, Towers GJ, Chen F, Riddell L, Walker BD, Ndung'u T, Leslie A, Buus S, Goulder P. J. Virol. 87 10889-10894 (2013)
  44. Effect of a tapasin mutant on the assembly of the mouse MHC class I molecule H2-K(d). Simone LC, Wang X, Tuli A, Solheim JC. Immunol. Cell Biol. 88 57-62 (2010)
  45. Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells. Stroobant V, Demotte N, Luiten RM, Leonhardt RM, Cresswell P, Bonehill A, Michaux A, Ma W, Mulder A, Van den Eynde BJ, van der Bruggen P, Vigneron N. Eur. J. Immunol. 42 1417-1428 (2012)
  46. Minimal observed impact of HLA genotype on hospitalization and severity of SARS-CoV-2 infection. Nguyen A, Yusufali T, Hollenbach JA, Nellore A, Thompson RF. HLA 99 607-613 (2022)
  47. A Micropolymorphism Altering the Residue Triad 97/114/156 Determines the Relative Levels of Tapasin Independence and Distinct Peptide Profiles for HLA-A(*)24 Allotypes. Badrinath S, Kunze-Schumacher H, Blasczyk R, Huyton T, Bade-Doeding C. J Immunol Res 2014 298145 (2014)
  48. Novel HLA class I associations with HIV-1 control in a unique genetically admixed population. Valenzuela-Ponce H, Alva-Hernández S, Garrido-Rodríguez D, Soto-Nava M, García-Téllez T, Escamilla-Gómez T, García-Morales C, Quiroz-Morales VS, Tapia-Trejo D, Del Arenal-Sánchez S, Prado-Galbarro FJ, Hernández-Juan R, Rodríguez-Aguirre E, Murakami-Ogasawara A, Mejía-Villatoro C, Escobar-Urias IY, Pinzón-Meza R, Pascale JM, Zaldivar Y, Porras-Cortés G, Quant-Durán C, Lorenzana I, Meza RI, Palou EY, Manzanero M, Cedillos RA, Aláez C, Brockman MA, Harrigan PR, Brumme CJ, Brumme ZL, Ávila-Ríos S, Reyes-Terán G, Mesoamerican HIV Project Group. Sci Rep 8 6111 (2018)
  49. The production, purification and crystallization of a soluble form of the nonclassical MHC HLA-G: the essential role of cobalt. Clements CS, Kjer-Nielsen L, Kostenko L, McCluskey J, Rossjohn J. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 62 70-73 (2006)
  50. Understanding the obstacle of incompatibility at residue 156 within HLA-B*35 subtypes. Manandhar T, Kunze-Schumacher H, Huyton T, Celik AA, Blasczyk R, Bade-Doeding C. Immunogenetics 68 247-260 (2016)
  51. CD74/DQA1 dimers predispose to the development of arthritis in humanized mice. David L, Gokhale A, Jois S, Johnson A, Behrens M, Luthra H, Taneja V. Immunology 147 204-211 (2016)
  52. Dynamic characterization of HLA-B*44 Alleles: A comparative molecular dynamics simulation study. Ozbek P. Comput Biol Chem 62 12-16 (2016)
  53. HLA tapasin independence: broader peptide repertoire and HIV control. Bashirova AA, Viard M, Naranbhai V, Grifoni A, Garcia-Beltran W, Akdag M, Yuki Y, Gao X, O'hUigin C, Raghavan M, Wolinsky S, Bream JH, Duggal P, Martinson J, Michael NL, Kirk GD, Buchbinder SP, Haas D, Goedert JJ, Deeks SG, Fellay J, Walker B, Goulder P, Cresswell P, Elliott T, Sette A, Carlson J, Carrington M. Proc Natl Acad Sci U S A 117 28232-28238 (2020)
  54. Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire. Illing PT, van Hateren A, Darley R, Croft NP, Mifsud NA, King S, Kostenko L, Bharadwaj M, McCluskey J, Elliott T, Purcell AW. Front Immunol 12 672737 (2021)
  55. Metal-triggered conformational reorientation of a self-peptide bound to a disease-associated HLA-B*27 subtype. Driller R, Ballaschk M, Schmieder P, Uchanska-Ziegler B, Ziegler A, Loll B. J Biol Chem 294 13269-13279 (2019)
  56. Peptidomes and Structures Illustrate Two Distinguishing Mechanisms of Alternating the Peptide Plasticity Caused by Swine MHC Class I Micropolymorphism. Wei X, Wang S, Li Z, Li Z, Qu Z, Wang S, Zou B, Liang R, Xia C, Zhang N. Front Immunol 12 592447 (2021)
  57. Selected HLA-B allotypes are resistant to inhibition or deficiency of the transporter associated with antigen processing (TAP). Geng J, Zaitouna AJ, Raghavan M. PLoS Pathog. 14 e1007171 (2018)
  58. The same major histocompatibility complex polymorphism involved in control of HIV influences peptide binding in the mouse H-2Ld system. Narayanan S, Kranz DM. J. Biol. Chem. 288 31784-31794 (2013)
  59. Balancing selection versus allele and supertype turnover in MHC class II genes in guppies. Herdegen-Radwan M, Phillips KP, Babik W, Mohammed RS, Radwan J. Heredity (Edinb) (2020)
  60. Comparative modeling of marsupial MHC class I molecules identifies structural polymorphisms affecting functional motifs. Daly K, Church WB, Nicholas K, Williamson P. J Exp Zool A Ecol Genet Physiol 307 611-624 (2007)
  61. Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules. Papadaki GF, Ani O, Florio TJ, Young MC, Danon JN, Sun Y, Dersh D, Sgourakis NG. Front Immunol 14 1116906 (2023)
  62. Genetic variation that determines TAPBP expression levels associates with the course of malaria in an HLA allotype-dependent manner. Walker-Sperling V, Digitale JC, Viard M, Martin MP, Bashirova A, Yuki Y, Ramsuran V, Kulkarni S, Naranbhai V, Li H, Anderson SK, Yum L, Clifford R, Kibuuka H, Ake J, Thomas R, Rowland-Jones S, Rek J, Arinaitwe E, Kamya M, Rodriguez-Barraquer I, Feeney ME, Carrington M. Proc Natl Acad Sci U S A 119 e2205498119 (2022)
  63. HLA polymorphism and tapasin independence influence outcomes of HIV and dengue virus infection. Di Pucchio T, Sekaly RP. Proc Natl Acad Sci U S A 117 31570-31572 (2020)
  64. HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome. Illing PT, Pymm P, Croft NP, Hilton HG, Jojic V, Han AS, Mendoza JL, Mifsud NA, Dudek NL, McCluskey J, Parham P, Rossjohn J, Vivian JP, Purcell AW. Nat Commun 9 4693 (2018)
  65. Intrinsic Folding Properties of the HLA-B27 Heavy Chain Revealed by Single Chain Trimer Versions of Peptide-Loaded Class I Major Histocompatibility Complex Molecules. Lenart I, Truong LH, Nguyen DD, Rasiukienė O, Tsao E, Armstrong J, Kumar P, McHugh K, Pereira BI, Maan BS, Garstka MA, Bowness P, Blake N, Powis SJ, Gould K, Nesbeth D, Antoniou AN. Front Immunol 13 902135 (2022)
  66. Mass Spectrometric Profiling of HLA-B44 Peptidomes Provides Evidence for Tapasin-Mediated Tryptophan Editing. Kaur A, Surnilla A, Zaitouna AJ, Mumphrey MB, Basrur V, Grigorova I, Cieslik M, Carrington M, Nesvizhskii AI, Raghavan M. J Immunol 211 1298-1307 (2023)
  67. Molecular determinants of chaperone interactions on MHC-I for folding and antigen repertoire selection. McShan AC, Devlin CA, Overall SA, Park J, Toor JS, Moschidi D, Flores-Solis D, Choi H, Tripathi S, Procko E, Sgourakis NG. Proc. Natl. Acad. Sci. U.S.A. 116 25602-25613 (2019)
  68. Preferential HLA-B27 Allorecognition Displayed by Multiple Cross-Reactive Antiviral CD8+ T Cell Receptors. Rowntree LC, van den Heuvel H, Sun J, D'Orsogna LJ, Nguyen THO, Claas FHJ, Rossjohn J, Kotsimbos TC, Purcell AW, Mifsud NA. Front Immunol 11 248 (2020)
  69. The Role of Dynamic DNA Methylation in Liver Transplant Rejection in Children. Ningappa M, Shao X, Ashokkumar C, Xu Q, Zeevi A, Grundberg E, Pastinen T, Sindhi R. Transplant Direct 8 e1394 (2022)
  70. The complex pattern of genetic associations of leprosy with HLA class I and class II alleles can be reduced to four amino acid positions. Dallmann-Sauer M, Fava VM, Gzara C, Orlova M, Van Thuc N, Thai VH, Alcaïs A, Abel L, Cobat A, Schurr E. PLoS Pathog 16 e1008818 (2020)


Quick links